Camostat (mesylate) (Standard)

Camostat (mesylate), with the CAS number 59721-29-8, is a well-characterized synthetic serine protease inhibitor that has garnered significant attention in both clinical practice and scientific research. It is also known by several aliases, including camostat mesilate, camostat methanesulfonate, Foy 305, Foy-S 980, and CV-001. Chemically, it is defined as 4-((4-((aminoiminomethyl)amino)benzoyl)oxy)benzene acetic acid 2-(dimethylamino)-2-oxoethyl ester methanesulfonate, with a molecular formula of C₂₁H₂₆N₄O₈S and a molecular weight of 494.5 Da.
First approved for medical use in Japan in 1985, camostat mesylate was initially indicated for alleviating acute symptoms of chronic pancreatitis, and later in 1994, it gained approval for treating postoperative reflux esophagitis. Its foundational mechanism lies in inhibiting a broad spectrum of serine proteases, including plasmin, kallikrein, thrombin, and trypsin—enzymes closely linked to inflammatory cascades and tissue damage.
In recent years, its research scope has expanded dramatically due to a critical discovery: it potently inhibits transmembrane protease, serine 2 (TMPRSS2), a host cell enzyme essential for priming the spike proteins of viruses like SARS-CoV-2 and influenza. This inhibition blocks viral entry into human cells, making it a key compound in antiviral research. Preclinical studies have further demonstrated its multifaceted activity, such as attenuating pancreatic fibrosis in vivo and regulating metabolic parameters in obese animal models.

Well-Defined Chemical Identity: Possesses a clear, documented chemical structure and consistent molecular properties, ensuring reproducibility in experimental settings.
Broad Protease Inhibition Spectrum: Targets multiple serine proteases (trypsin, kallikrein, plasmin, thrombin, TMPRSS2) rather than a single enzyme, supporting diverse research applications.
Favorable Solubility Profile: Soluble in both water and DMSO at concentrations up to 50 mg/mL (and up to 125 mg/mL in DMSO for select preparations), facilitating easy formulation for in vitro and in vivo experiments.
Stable Physical Form: Appears as an off-white powder, with well-documented storage conditions (desiccated, frozen, and dark environment) that maintain its activity for up to 2 years in powder form.

Pancreatitis Research: Used to study disease pathogenesis by inhibiting trypsinogen activation and reducing pancreatic inflammation/fibrosis; supports development of novel treatments for chronic pancreatitis.
Antiviral Studies: A core compound for investigating TMPRSS2-dependent viral entry, particularly in research on SARS-CoV-2, influenza, and other coronaviruses.
Inflammatory and Fibrotic Disease Research: Validated for exploring mechanisms of fibrosis (e.g., pancreatic fibrosis) and inflammation, via suppression of cytokines like TNF-α, IL-6, and TGF-β.
Metabolic Disorder Research: Employed to study metabolic regulation, as it reduces body weight, blood glucose, and liver lipidosis in obese mouse models by inhibiting trypsin.
Drug Development and Formulation: Serves as a standard reference compound for developing new serine protease inhibitors or optimizing delivery systems for existing protease-targeting drugs.

Researchers working with camostat mesylate often seek complementary compounds in serine protease inhibition and antiviral research. Relevant products include other TMPRSS2 inhibitors (such as nafamostat mesylate), broad-spectrum serine protease inhibitors targeting similar enzyme families (e.g., aprotinin), and compounds modulating viral entry pathways (like ACE2 inhibitors). Additionally, reagents for studying downstream signaling of inhibited proteases—such as TNF-α, IL-6, and TGF-β ELISA kits—are commonly paired with camostat mesylate for mechanistic studies. If you are interested in related products, you can directly contact us or inquire about product customization services.